

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

**VOLUNTARY ANNOUNCEMENT
CLARIFICATION AND UNAUDITED BUSINESS UPDATE IN
RELATION TO MEDIA COVERAGE RELATING TO
COMMERCIALIZATION PROGRESS OF HUATANGNING (華堂寧®)**

This announcement is voluntarily made pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The board of directors (the “**Board**”) of Hua Medicine (the “**Company**”) is aware of certain media coverage on 16 February 2023 regarding the current cumulative sales of HuaTangNing (華堂寧®) in mainland China since its approval and commercial launch at the end of October 2022. For the period from first commercial sales through January 31, 2023, approximately 148,000 packs (unaudited) of HuaTangNing (華堂寧®) have been sold, generating sales revenues of approximately RMB49 million (unaudited).

The Company would like to remind shareholders and potential investors that the information contained in this announcement is unaudited and represents preliminary statistics and a preliminary assessment based on management accounts of the Company and its subsidiaries, which has not been audited or reviewed by the Company’s auditor and may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such internal information.

The Company is in the process of reviewing its financial results for the financial year ended 31 December 2022 and will update the market on its financial performance during the past financial year by way of an announcement to be published on the websites of the Stock Exchange and the Company, which is currently anticipated to be around the end of March 2023.

The Company would also like to remind its shareholders and potential investors that media coverage about the Company are not authorised by, and do not represent the views of, the Company. Only information published by the Company and disclosed on the Stock Exchange website at www.hkexnews.hk and the Company’s website at www.huamedicine.com should be relied upon for information about, and from, the Company.

Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, HuaTangNing (華堂寧®) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board

Dr. Li Chen

Chief Executive Officer and Executive Director

Shanghai, 16th February 2023

As of the date of this announcement, the Board comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Ms. Wei Zhao as non-executive Directors; and Mr. William Robert Keller, Mr. Junling Liu, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.